An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers ; day:13 ; month:03 ; year:2024 ; extent:16
Advanced science ; (13.03.2024) (gesamt 16)
- Urheber
-
Yu, Yueh‐Hsiang
Tian, Wei‐Ting
Grauffel, Cédric
Lin, Wei‐Chen
Hsieh, Ming‐Yu
Wu, Pei‐Wen
Lee, Hui‐Ju
Peng, Chi‐Jiun
Lin, Pei‐Hsuan
Chu, Hsing‐Mao
Lim, Carmay
Chang, Tse Wen
- DOI
-
10.1002/advs.202307852
- URN
-
urn:nbn:de:101:1-2024031314041981054070
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yu, Yueh‐Hsiang
- Tian, Wei‐Ting
- Grauffel, Cédric
- Lin, Wei‐Chen
- Hsieh, Ming‐Yu
- Wu, Pei‐Wen
- Lee, Hui‐Ju
- Peng, Chi‐Jiun
- Lin, Pei‐Hsuan
- Chu, Hsing‐Mao
- Lim, Carmay
- Chang, Tse Wen
Ähnliche Objekte (12)
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates